Literature DB >> 28053739

Ocular myasthenia gravis in a person with tetraplegia presenting challenges in diagnosis and management.

Sumitha Gounden1, Bonne Lee2, Ross Mellick2, Susan B Rutkowski3, James W Middleton3.   

Abstract

We report the first case of ocular myasthenia gravis (OMG) in a patient with complete tetraplegia, highlighting diagnostic and management challenges. Spinal multidisciplinary rural clinic and specialised inpatient Spinal Cord Injury Unit, NSW, Australia. A 61-year-old man with established C5 AIS A tetraplegia, presented with sudden onset of diplopia and bilateral ptosis, later diagnosed as OMG, in context of other complex co-morbidities, including a cervical cord syrinx, obstructive sleep apnoea and labile blood pressure. Clinical findings were consistent with fluctuating bilateral partial third and sixth nerve palsies. Acetylcholine receptor antibodies were negative, but electromyography demonstrated muscle fatigue. The ocular signs responded well to pyridostigmine. Medications taken before diagnosis, including solifenacin for neurogenic bladder overactivity, were ceased to avoid attenuating the anti-cholinesterase effect. However, the unopposed anti-cholinesterase activity led to frequent and painful abdominal spasms, associated with uncontrolled detrusor hyperreflexia and worsening autonomic dysreflexia (AD). A trans-vesical phenol block to treat this provided only short-lasting benefit. Pyridostigmine was ceased to avoid provoking his abdominal spasms and his regular medications were recommenced. It was decided that the most appropriate treatment for his distressing diplopia was an eye patch. After discharge home, he continued to experience problems with recurrent urinary tract infections, abdominal spasms, episodic postural hypotension and AD. After 5 months, the patient died from an acute myocardial infarction. This case report contributes new knowledge about the rare presentation of OMG in a person with chronic tetraplegia.

Entities:  

Keywords:  Neurological disorders; Spinal cord diseases

Year:  2016        PMID: 28053739      PMCID: PMC5129383          DOI: 10.1038/scsandc.2015.37

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  7 in total

Review 1.  Myasthenia gravis.

Authors:  A Vincent; J Palace; D Hilton-Jones
Journal:  Lancet       Date:  2001-06-30       Impact factor: 79.321

2.  Myasthenic crisis after botulinum toxin.

Authors:  G Borodic
Journal:  Lancet       Date:  1998-12-05       Impact factor: 79.321

Review 3.  The course of myasthenia gravis and therapies affecting outcome.

Authors:  D Grob; E L Arsura; N G Brunner; T Namba
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

4.  Superimposed myasthenia gravis in chronic spinal cord injury: a case report.

Authors:  S Kolli; K M Mathew; P Thumbikat; M R McClelland; K P S Nair
Journal:  Spinal Cord       Date:  2010-12-21       Impact factor: 2.772

5.  Life expectancy after spinal cord injury: a 50-year study.

Authors:  J W Middleton; A Dayton; J Walsh; S B Rutkowski; G Leong; S Duong
Journal:  Spinal Cord       Date:  2012-05-15       Impact factor: 2.772

6.  Sudden dysphagia in an elderly, quadriparetic patient.

Authors:  J-F Kaux; F Ongena; F Wang; J-M Crielaard; M Foidart-Dessalle
Journal:  Ann Phys Rehabil Med       Date:  2009-02-13

7.  Myasthenia gravis with superimposed spinal cord injury: a case report.

Authors:  Che-Sheng Lin; Juei-Hsiang Wang; Yen-Ho Wang; Shin-Liang Pan
Journal:  J Rehabil Med       Date:  2008-08       Impact factor: 2.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.